Skip to NavigationSkip to content

Silence Therapeutics appoints Thomas Christely

Published on: 21/09/11

UK-headquartered biotech Silence Therapeutics has appointed Thomas Christély as chief executive.

He was instrumental in the merger of Silence Therapeutics AG (formerly Atugen AG) with Silence Therapeutics plc (formerly SR Pharma plc), having joined Atugen AG in 2001 as chief financial officer.

He subsequently served as chief operating officer from 2002 before being appointed chief executive in 2006.

Prior to this Thomas was senior VP and chief financial officer at OXO Chemie AG, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc. in San Francisco, where he stayed from 1997 until 2000

He will be based at Silence’s facility in Berlin.

Jerry Randall, chairman of Silence Therapeutics, said: “Now that Silence has become a wholly European company it is appropriate to have a chief executive based in Europe.

“Thomas’ experience with the team and the science will ensure continuity as we move forward. We are confident that Thomas has the vision, expertise and experience necessary to move the Company toward the achievement of its corporate and clinical objectives.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches